Sfoglia per Autore
Anticoagulant Therapy in Patients with Atrial Fibrillation and Risk of Bleeding: Interim Analysis: Tyrion Study
2018-01-01 Ferraro, S; Convertino, I; Salvadori, S; Pieroni, S; Pecori, A; Franchini, M; De Carlo, I; Kirchmayer, U; Corona, T; Parrilli, M; Rossi, M; Vannacci, A; Blandizzi, C; Tuccori, M
A Model-Based Analysis on Direct Costs of Adverse Drug Events and Related Cost-Savings Achievable by their Prevention in Tuscany, Italy
2018-01-01 Convertino, I; Salvadori, S; Pecori, A; Galiulo, Mt; Ferraro, S; Parrilli, M; Corona, T; Turchetti, G; Blandizzi, C; Tuccori, M
The usefulness of listening social media for pharmacovigilance purposes: a systematic review
2018-01-01 Convertino, Irma; Ferraro, Sara; Blandizzi, Corrado; Tuccori, Marco
Switching from infliximab-originator to infliximab-biosimilar in rheumatologic patients: The clinical impact in Tuscan Region, Italy
2019-01-01 Convertino, I; Tuccori, M; Lucenteforte, E; Mosca, M; Turchetti, G; Lorenzoni, V; Trieste, L; Ferraro, S; Leonardi, L; Roberto, G; Luciano, N; Blandizzi, C; Gini, R
Potential Direct Costs of Adverse Drug Events and Possible Cost Savings Achievable by their Prevention in Tuscany, Italy: A Model-Based Analysis
2019-01-01 Convertino, Irma; Salvadori, Stefano; Pecori, Alessandro; Galiulo, Maria Teresa; Ferraro, Sara; Parrilli, Maria; Corona, Tiberio; Turchetti, Giuseppe; Blandizzi, Corrado; Tuccori, Marco
The Anti-TNF Drugs and the Risk of Lymphoma, Skin Cancer and Melanoma: A Signal Detection Analysis
2019-01-01 Leonardi, L; Fornili, M; Convertino, I; Lucenteforte, E; Del Lungo, M; Ferraro, S; Blandizzi, C; Giovannetti, L; Baglietto, L; Parrilli, M; Borsi, V; Di Giorgio, D
THE ECONOMIC IMPACT OF THE INTRODUCTION OF INFLIXIMAB-BIOSIMILAR: AN EMPIRICAL ANALYSIS USING THE TUSCANY HEALTHCARE ADMINISTRATIVE DATABASES
2019-01-01 Lorenzoni, V; Convertino, I; Lucenteforte, E; Ferraro, S; Leonardi, L; Roberto, G; Luciano, N; Cazzato, M; Blandizzi, C; Gini, R; Tuccori, M; Mosca, M; Turchetti, G
Recommendations by the Tuscan Health Authority to Use Infliximab-Biosimilar in the Clinical Practice: Safety Impact
2019-01-01 Convertino, I; Lucenteforte, E; Lorenzoni, V; Turchetti, G; Trieste, L; Roberto, G; Cazzato, M; Mosca, M; Ferraro, S; Leonardi, L; Luciano, N; Gini, R; Blandizzi, C; Tuccori, M
Antibiotic Drugs and Unresolved Sensory Side Effects: Analysis of Eudravigilance Database of Suspected Adverse Drug Reaction Reports
2019-01-01 Ferraro, S; Leonardi, L; Blandizzi, C; Convertino, I; Tuccori, M
Listening Social Media for Pharmacovigilance Objectives: Which Usefulness?
2019-01-01 Convertino, I; Leonardi, L; Tuccori, M; Ferraro, S; Blandizzi, C
The Economic Impact of the Introduction of Infliximab-Biosimilar: Preliminary Results from a Study on Rheumatologic Patients in Tuscany, Italy
2019-01-01 Lorenzoni, V; Trieste, L; Mosca, M; Convertino, I; Tuccori, M; Lucenteforte, E; Ferraro, S; Leonardi, L; Roberto, G; Luciano, N; Blandizzi, C; Gini, R; Turchetti, G
Unresolved gustatory, olfactory and auditory adverse drug reactions to antibiotic drugs: a survey of spontaneous reporting to Eudravigilance
2019-01-01 Ferraro, S.; Convertino, I.; Leonardi, L.; Blandizzi, C.; Tuccori, M.
Anti-tumor Necrosis Factor Drugs and Risk of Lymphoma in Patients with Inflammatory Bowel Disease
2019-01-01 Blandizzi, C; Tuccori, M; Ferraro, S; Leonardi, L; Convertino, I
Is There a Risk of Lymphoma Associated With Anti-tumor Necrosis Factor Drugs in Patients With Inflammatory Bowel Disease? A Systematic Review of Observational Studies
2019-01-01 Ferraro, Sara; Leonardi, Luca; Convertino, Irma; Blandizzi, Corrado; Tuccori, Marco
Anticoagulant Therapy and Risk of Bleeding in Patients with Atrial Fibrillation of Four Italian Regions: The TYRION Study
2019-01-01 Convertino, I; Leonardi, L; Tuccori, M; Ferraro, S; Salvadori, S; Franchini, M; De Carlo, I; Kirchmayer, U; Corona, T; Riengler, S; Menditto, E; Parrilli, M; Rossi, M; Orlando, V; Pieroni, S; Vannacci, A
The Impact of the COVID-19 “Infodemic” on Drug-Utilization Behaviors: Implications for Pharmacovigilance
2020-01-01 Tuccori, M.; Convertino, I.; Ferraro, S.; Cappello, E.; Valdiserra, G.; Focosi, D.; Blandizzi, C.
Trajectories of use of biologic disease modifying antirheumatic drugs in rheumatoid arthritis: A cohort study of Tuscan patients, Italy
2020-01-01 Convertino, I; Giometto, S; Gini, R; Cazzato, M; Valdiserra, G; Cappello, E; Ferraro, S; Fornili, M; Turchetti, G; Lorenzoni, V; Trieste, L; Mosca, M; Blandizzi, C; Tuccori, M; Lucenteforte, E
Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients
2020-01-01 Convertino, I.; Tuccori, M.; Ferraro, S.; Valdiserra, G.; Cappello, E.; Focosi, D.; Blandizzi, C.
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline
2020-01-01 Tuccori, M.; Ferraro, S.; Convertino, I.; Cappello, E.; Valdiserra, G.; Blandizzi, C.; Maggi, F.; Focosi, D.
Time to biologic treatment and to total colectomy associated with diagnostic delay in ulcerative colitis: Analysis of an Italian regional administrative healthcare database
2020-01-01 Ferraro, S; Bartolini, C; Bertani, L; Convertino, I; Lucenteforte, E; Costa, F; Valdiserra, G; Cappello, E; Blandizzi, C; Gini, R; Tuccori, M
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Anticoagulant Therapy in Patients with Atrial Fibrillation and Risk of Bleeding: Interim Analysis: Tyrion Study | 1-gen-2018 | Ferraro, S; Convertino, I; Salvadori, S; Pieroni, S; Pecori, A; Franchini, M; De Carlo, I; Kirchmayer, U; Corona, T; Parrilli, M; Rossi, M; Vannacci, A; Blandizzi, C; Tuccori, M | |
| A Model-Based Analysis on Direct Costs of Adverse Drug Events and Related Cost-Savings Achievable by their Prevention in Tuscany, Italy | 1-gen-2018 | Convertino, I; Salvadori, S; Pecori, A; Galiulo, Mt; Ferraro, S; Parrilli, M; Corona, T; Turchetti, G; Blandizzi, C; Tuccori, M | |
| The usefulness of listening social media for pharmacovigilance purposes: a systematic review | 1-gen-2018 | Convertino, Irma; Ferraro, Sara; Blandizzi, Corrado; Tuccori, Marco | |
| Switching from infliximab-originator to infliximab-biosimilar in rheumatologic patients: The clinical impact in Tuscan Region, Italy | 1-gen-2019 | Convertino, I; Tuccori, M; Lucenteforte, E; Mosca, M; Turchetti, G; Lorenzoni, V; Trieste, L; Ferraro, S; Leonardi, L; Roberto, G; Luciano, N; Blandizzi, C; Gini, R | |
| Potential Direct Costs of Adverse Drug Events and Possible Cost Savings Achievable by their Prevention in Tuscany, Italy: A Model-Based Analysis | 1-gen-2019 | Convertino, Irma; Salvadori, Stefano; Pecori, Alessandro; Galiulo, Maria Teresa; Ferraro, Sara; Parrilli, Maria; Corona, Tiberio; Turchetti, Giuseppe; Blandizzi, Corrado; Tuccori, Marco | |
| The Anti-TNF Drugs and the Risk of Lymphoma, Skin Cancer and Melanoma: A Signal Detection Analysis | 1-gen-2019 | Leonardi, L; Fornili, M; Convertino, I; Lucenteforte, E; Del Lungo, M; Ferraro, S; Blandizzi, C; Giovannetti, L; Baglietto, L; Parrilli, M; Borsi, V; Di Giorgio, D | |
| THE ECONOMIC IMPACT OF THE INTRODUCTION OF INFLIXIMAB-BIOSIMILAR: AN EMPIRICAL ANALYSIS USING THE TUSCANY HEALTHCARE ADMINISTRATIVE DATABASES | 1-gen-2019 | Lorenzoni, V; Convertino, I; Lucenteforte, E; Ferraro, S; Leonardi, L; Roberto, G; Luciano, N; Cazzato, M; Blandizzi, C; Gini, R; Tuccori, M; Mosca, M; Turchetti, G | |
| Recommendations by the Tuscan Health Authority to Use Infliximab-Biosimilar in the Clinical Practice: Safety Impact | 1-gen-2019 | Convertino, I; Lucenteforte, E; Lorenzoni, V; Turchetti, G; Trieste, L; Roberto, G; Cazzato, M; Mosca, M; Ferraro, S; Leonardi, L; Luciano, N; Gini, R; Blandizzi, C; Tuccori, M | |
| Antibiotic Drugs and Unresolved Sensory Side Effects: Analysis of Eudravigilance Database of Suspected Adverse Drug Reaction Reports | 1-gen-2019 | Ferraro, S; Leonardi, L; Blandizzi, C; Convertino, I; Tuccori, M | |
| Listening Social Media for Pharmacovigilance Objectives: Which Usefulness? | 1-gen-2019 | Convertino, I; Leonardi, L; Tuccori, M; Ferraro, S; Blandizzi, C | |
| The Economic Impact of the Introduction of Infliximab-Biosimilar: Preliminary Results from a Study on Rheumatologic Patients in Tuscany, Italy | 1-gen-2019 | Lorenzoni, V; Trieste, L; Mosca, M; Convertino, I; Tuccori, M; Lucenteforte, E; Ferraro, S; Leonardi, L; Roberto, G; Luciano, N; Blandizzi, C; Gini, R; Turchetti, G | |
| Unresolved gustatory, olfactory and auditory adverse drug reactions to antibiotic drugs: a survey of spontaneous reporting to Eudravigilance | 1-gen-2019 | Ferraro, S.; Convertino, I.; Leonardi, L.; Blandizzi, C.; Tuccori, M. | |
| Anti-tumor Necrosis Factor Drugs and Risk of Lymphoma in Patients with Inflammatory Bowel Disease | 1-gen-2019 | Blandizzi, C; Tuccori, M; Ferraro, S; Leonardi, L; Convertino, I | |
| Is There a Risk of Lymphoma Associated With Anti-tumor Necrosis Factor Drugs in Patients With Inflammatory Bowel Disease? A Systematic Review of Observational Studies | 1-gen-2019 | Ferraro, Sara; Leonardi, Luca; Convertino, Irma; Blandizzi, Corrado; Tuccori, Marco | |
| Anticoagulant Therapy and Risk of Bleeding in Patients with Atrial Fibrillation of Four Italian Regions: The TYRION Study | 1-gen-2019 | Convertino, I; Leonardi, L; Tuccori, M; Ferraro, S; Salvadori, S; Franchini, M; De Carlo, I; Kirchmayer, U; Corona, T; Riengler, S; Menditto, E; Parrilli, M; Rossi, M; Orlando, V; Pieroni, S; Vannacci, A | |
| The Impact of the COVID-19 “Infodemic” on Drug-Utilization Behaviors: Implications for Pharmacovigilance | 1-gen-2020 | Tuccori, M.; Convertino, I.; Ferraro, S.; Cappello, E.; Valdiserra, G.; Focosi, D.; Blandizzi, C. | |
| Trajectories of use of biologic disease modifying antirheumatic drugs in rheumatoid arthritis: A cohort study of Tuscan patients, Italy | 1-gen-2020 | Convertino, I; Giometto, S; Gini, R; Cazzato, M; Valdiserra, G; Cappello, E; Ferraro, S; Fornili, M; Turchetti, G; Lorenzoni, V; Trieste, L; Mosca, M; Blandizzi, C; Tuccori, M; Lucenteforte, E | |
| Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients | 1-gen-2020 | Convertino, I.; Tuccori, M.; Ferraro, S.; Valdiserra, G.; Cappello, E.; Focosi, D.; Blandizzi, C. | |
| Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline | 1-gen-2020 | Tuccori, M.; Ferraro, S.; Convertino, I.; Cappello, E.; Valdiserra, G.; Blandizzi, C.; Maggi, F.; Focosi, D. | |
| Time to biologic treatment and to total colectomy associated with diagnostic delay in ulcerative colitis: Analysis of an Italian regional administrative healthcare database | 1-gen-2020 | Ferraro, S; Bartolini, C; Bertani, L; Convertino, I; Lucenteforte, E; Costa, F; Valdiserra, G; Cappello, E; Blandizzi, C; Gini, R; Tuccori, M |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile